You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

110 search results for: patient burden

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​
expert video

Targeting Type 2 Inflammation: ​Skin Barrier Normalization​

Dermatology
Highlights from ESPD 2023 ADVENT: Uncovering how type 2 inflammation influences skin barrier dysfunction in atopic dermatitis.
View more
High <b>Burden</b> of Atopic Dermatitis in Children
expert video

High Burden of Atopic Dermatitis in Children

Dermatology
Explore the debilitating effects that impact day-to-day functioning in pediatric patients with atopic dermatitis – a short soundbite from EADV 2022.
View more
AD, PN, and CSU: Distinct, Pruritic Diseases
expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

Dermatology
Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.
View more
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Podcast

ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis

Dermatology
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.
View more
Type 2 Inflammation Underpins Pediatric Severe Asthma
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

Pulmonology
Learn about the role type 2 inflammation plays in the burden and pathophysiology of severe asthma in pediatric patients.
View more
ADVENT On Air | Dysphagia in EoE: How Can You See Beyond <b>Patient</b>s’ Adaptive Behaviors?
Podcast

ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

Gastroenterology
Learn from Dr. Hirano and Dr. Marcon as they discuss how to unmask EoE symptoms that may be hidden by patients' coping mechanisms.
View more
Differences in Itch in AD, PN, and CSU
expert video

Differences in Itch in AD, PN, and CSU

Dermatology
Dr. Shawn Kwatra reviews the distinct characteristics of itch, and the associated patient burden in AD, PN, and CSU.
View more
ESPGHAN 2024 | Clinical Management of Young Children With EoE
expert video

ESPGHAN 2024 | Clinical Management of Young Children With EoE

Gastroenterology
Dr. Dhandapani Ashok highlights treatment options for patients with EoE aged 12 years and younger and the importance of shared decision-making.
View more
Interdisciplinary Care for EoE: Experts Offer Food for Thought
expert video

Interdisciplinary Care for EoE: Experts Offer Food for Thought

Gastroenterology
Join Drs. Ikuo Hirano, Margaret Collins, and Jason Lee as they discuss their clinical experiences with interdisciplinary care of patients with EoE
View more
Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma
Infographic

Type 2 Inflammation Is a Significant Driver of Pediatric Severe Asthma

Pulmonology
Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients
View more
Skin Dyspigmentation In Prurigo Nodularis (PN)
interactivity

Skin Dyspigmentation In Prurigo Nodularis (PN)

Dermatology
This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.
View more
The <b>Burden</b> of Atopic Dermatitis in Children – Skin Infections and More Severe Disease
expert video

The Burden of Atopic Dermatitis in Children – Skin Infections and More Severe Disease

Dermatology
Dr. Mark Koh talks about skin infections and their impact on disease severity.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region